This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif., March 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today the pricing of its follow-on offering of 2,875,000 shares of its common stock at $20.75 per share, before underwriting discounts and commissions. All of the common stock is being offered by Hyperion. In addition, the underwriters have a 30-day option to purchase up to an additional 431,250 shares of common stock from Hyperion to cover over-allotments, if any. The offering is expected to close on March 13, 2013, subject to customary closing conditions.
Leerink Swann LLC and Cowen and Company, LLC are serving as joint book-running managers for the proposed offering. Needham & Company, LLC and JMP Securities LLC are acting as co-managers for the proposed offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 7, 2013. This offering is being made only by means of a prospectus, copies of which may be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by calling (800) 808-7525, ext. 4814, and Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by calling (631) 274-2806, or faxing (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. For more information, please visit